- Home
- KPTI
as 04-11-2025 4:00pm EST
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | NEWTON |
| Market Cap: | 33.6M | IPO Year: | 2013 |
| Target Price: | $61.00 | AVG Volume (30 days): | 168.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -14.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.51 - $21.30 | Next Earning Date: | 05-07-2025 |
| Revenue: | $145,237,000 | Revenue Growth: | -0.55% |
| Revenue Growth (this year): | 4.87% | Revenue Growth (next year): | 16.29% |
Stock Insider Trading Activity of Karyopharm Therapeutics Inc. (KPTI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Paulson Richard A. | KPTI | President and CEO | Apr 4 '25 | Sell | $3.74 | 245 | $916.30 | 82,739 | |
| Poulton Stuart | KPTI | EVP, Chief Development Officer | Mar 4 '25 | Sell | $6.29 | 3,548 | $22,316.92 | 27,414 | |
| Cheng Sohanya Roshan | KPTI | EVP & Chief Commercial Officer | Mar 4 '25 | Sell | $6.29 | 3,445 | $21,669.05 | 34,314 | |
| Paulson Richard A. | KPTI | President and CEO | Mar 4 '25 | Sell | $6.29 | 11,694 | $73,555.26 | 82,739 | |
| Mano Michael | KPTI | SVP, General Counsel&Secretary | Mar 4 '25 | Sell | $6.29 | 2,793 | $17,567.97 | 21,047 | |
| Rangwala Reshma | KPTI | EVP & Chief Medical Officer | Mar 4 '25 | Sell | $6.29 | 3,587 | $22,562.23 | 29,272 | |
| Abate Kristin | KPTI | Chief Accounting Officer | Mar 4 '25 | Sell | $6.29 | 571 | $3,591.59 | 9,713 | |
| Poulton Stuart | KPTI | EVP, Chief Development Officer | Feb 18 '25 | Sell | $0.63 | 5,914 | $3,725.82 | 27,414 | |
| Paulson Richard A. | KPTI | President and CEO | Feb 4 '25 | Sell | $0.65 | 4,099 | $2,664.35 | 82,739 |
Latest Karyopharm Therapeutics Inc. News
KPTI Breaking Stock News: Dive into KPTI Ticker-Specific Updates for Smart Investing
MT Newswires
11 days ago
RBC Lowers Price Target on Karyopharm Therapeutics to $43 From $45, Keeps Outperform Rating
PR Newswire
12 days ago
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TipRanks
12 days ago
Biotech stocks slide as Marks resignation seen being negative for sector
PR Newswire
a month ago
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
2 months ago
Karyopharm Therapeutics to Implement 1-for-15 Reverse Stock Split
PR Newswire
2 months ago
Karyopharm Announces 1-for-15 Reverse Stock Split
Simply Wall St.
2 months ago
Karyopharm Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
GuruFocus.com
2 months ago
Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Call Highlights: Navigating Revenue ...
Compare KPTI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KPTI Karyopharm Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.